<i id='C91FD23764'><strike id='C91FD23764'><tt id='C91FD23764'><pre id='C91FD23764'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Virginia high school admissions case could be legal follow 
Cue Health, Covid 
Affirmative action in medical school literally saved lives 
Inflation cooled significantly in June, bringing price hikes close to normal levels 
Drug repurposing or repositioning? The language matters 
China sends large group of warplanes, navy ships towards Taiwan in forceful display 
Duchenne breakthrough therapy leaves behind pioneering families 
One Duchenne patient's bittersweet hope for new treatment 
Psychedelics group wrestles with new pharma identity 
Biogen joins immunology wave with $1.15 billion acquisition of HI
Duchenne breakthrough therapy leaves behind pioneering families 
Superbugs, antibiotic resistance get scrutiny in congress 
Hollywood unions extend contract negotiations for actors 
Bird flu surveillance in wastewater gets boost from consortium 
How one medical school became remarkably diverse 
